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Summary Adjuvant chemotherapy with fluorouracil (FU) and levamisole or FU/leucovorin (LV) has been established as effective adjuvant
treatment for patients with stage IlIl colon cancer. Among several other promising treatment strategies in resected colon cancer,
intraperitoneal anti-cancer drug administration with its appealing rationale of counteracting microscopic residual disease on peritoneal
surfaces and occult metachronous liver metastases by achieving high intraportal drug concentrations has not yet undergone sufficient clinical
evaluation. To determine whether a combination of this locoregional therapeutic concept with systemic intravenous administration of FU/LV
would yield better results than conventional adjuvant chemoimmunotherapy with FU/levamisole, the present randomized study was initiated.
A total of 241 patients with resected stage IlIl or high-risk stage II (T4NOMO) colon cancer were randomly assigned to 'standard therapy' with
FU and levamisole, given for a duration of 6 months, or to an investigational arm, consisting of LV 200 mg m-2 plus FU 350 mg m-2, both
administered intravenously (days 1-4) and intraperitoneally (days 1 and 3) every 4 weeks for a total of six courses. In patients with stage 11
disease, no significant difference was noted between the two arms after a median follow-up time of 4 years (range 2.5-6 years). Among 196
eligible patients with stage IlIl disease, however, a comparative analysis of the two treatment groups suggested both an improvement in
disease-free survival (P= 0.0014) and a survival advantage (P= 0.0005), with an estimated 43% reduction in mortality rate (95% confidence
interval 26-70%) in favour of the investigational arm. In agreement with its theoretical rationale, combined intrapertoneal and intravenous
FU/LV was particularly effective in reducing locoregional tumour recurrences with or without liver or other organ site involvement (9 vs 25
patients in the FU/levamisole arm; P= 0.005). Treatment-associated side-effects were infrequent and generally mild in both arms, although a
lower rate of severe (WHO grade 3) adverse reactions was noted in patients receiving locoregional plus intravenous chemotherapy (3% vs
12%; P = 0.01). The results of this trial suggest that combined intraperitoneal plus systemic intravenous chemotherapy with FU/LV is a
promising adjuvant treatment strategy in patients with surgically resected stage IlIl colon carcinoma.
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Adenocarcinoma ofthe colon is one of the most common internal
malignancies, affecting about 1 person in 20 in the Western world
(Cohen etal, 1993). Although mostpatients present withsurgically
resectable disease, almost half die of the cancer because of occult
micrometastases already present at the time ofinitial diagnosis. In
recent years, however, there have been some advances. Infact, it is
now over 5 years since the publication of two randomized trials
showing that fluorouracil(FU) and levamisole reduced therelapse
rateby 40% and mortality by a third inpatients with node-positive
colon cancer (Laurie et al, 1989; Moertel et al, 1990). The final
report ofthese data was recently published, showing 168 deaths in
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untreated control patients vs only 121 in those who received adju-
vant treatment (P >0.005) (Moertel etal, 1995). Despite these data
and recommendation of this regimen as standard therapy for
Dukes' C patients since the consensus conference of the National
Institute of Health (NIH, 1990), many (European) surgeons and
oncologists remained sceptical about its benefits (Reynolds, 1995;
Wassner and Heidemann, 1996; Zalcberg et al, 1996). The adju-
vant FUl/evamisole regimen has been defined empirically; the
exact therapeutic role and anti-tumour mechanism ofaction ofthe
antihelmintic drug levamisole remains uncertain, treatment is not
without toxicity (Delorenzo and Stewart, 1990; Wassner and
Heidemann, 1996), compliance with weekly drug administration
was noted to be poor (Delorenzo and Stewart, 1990; Moertel et al,
1990), and in patients with metastatic disease this combination
does not show any advantage over FU alone (Buroker et al, 1985).
The most active chemotherapeutic regimen in patients with
advanced colorectal cancerrepresents the biochemical modulation
of FU by leucovorin (LV). A number of prospective randomized
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trials have demonstrated its superior response activity compared
with FU monotherapy (Advanced Colorectal Cancer Meta-
Analysis Project, 1992). There is also accumulating evidence that
FU/LV is very effective in the adjuvant treatment setting
(Wolmark et al, 1993; Francini et al, 1994; IMPACT Trial, 1995;
O'Connell et al, 1997), and recent data suggest that it even may be
superior in terms of survival and disease-free survival compared
with FU/levamisole (Wolmark et al, 1996).
In the present study, we have randomized patients between
adjuvant FU plus LV administered both by systemic intravenous
(i.v.) infusion and intraperitoneally (i.p.) and 'standard adjuvant
therapy' with FU plus levamisole. The rationale for the combined
i.p. + i.v. mode of drug administration was to counteract tumour
dissemination via haematogenous/lymphogenous spread as well
as perioperative implantation oftumour cells in the resection site
and in peritoneal surfaces, which represent common sites of
colonic cancer recurrence (Sugarbaker et al, 1985; 1996; Cunliffe
and Sugarbaker, 1989). Pharmacokinetic studies with i.p. FU
have demonstrated that tumoricidal doses ofthe drug are present
in the abdominal cavity for at least 8 h after instillation (Cunliffe
and Sugarbaker, 1989). In addition, up to ten times the level of
drug is seen in the portal vein than is noted in the peripheral
blood (Sugarbaker et al, 1985; Rougier and Nordlinger, 1993).
Thus, i.p./i.v. administration of FU/LV could not only protect
peritoneal surfaces, but also counteract occult metachronous
liver metastases by achieving high intraportal/intrahepatic drug
concentrations. Feasibility, tolerance and the therapeutic poten-
tial of this theoretically appealing adjuvant treatment approach
has been demonstrated in a previous study in patients with stage
III and high-risk stage II colon cancer: after almost 5 years of
follow-up, a significant difference in recurrence-free survival
and an overall survival advantage of 78% vs 63% was noted in
patients given i.p. + i.v. FU/LV compared with an untreated
control (Scheithauer et al, 1995).
PATIENTS AND METHODS
Patient selection
To be included in the study, patients were required to have under-
gone curative en bloc resection ofan adenocarcinoma ofthe colon
without gross ormicroscopic evidence ofresidual disease. Patients
had to have histopathological diagnosis of stage II with invasion
extending at least to the serosa or pericolonic fat (Dukes' B2) or
stage III (Dukes' C) disease. At least ten regional lymphnodes had
to be examined. Additional eligibility criteria included age 75 years
or younger, a World Health Organization (WHO) performance
status less than 2, normal bone marrow (leucocytes > 4 000Rl-1,
thrombocytes > 100 000 1-1), liver (bilirubin <1.5 mg dl-1; trans-
aminase level less than two times the upper limit of normal), and
renal functions (serum creatinine <1.5 mg dl-1 ). Patients were
excluded if they had rectal cancer (defined using this protocol as
any lesion that required the opening of the pelvic peritoneum to
define the distal extent ofthe tumour), any other cancer except for
superficial skin carcinoma or in situ carcinoma of the cervix, or
any other severe concomitant disease that would preclude a
normal life expectancy of at least 5 years. No other adjuvant
therapy was allowed. Eligibility was determined by careful review
of study forms, operative and pathology reports. Entry into the
study was allowed no earlierthan 1 week and no laterthan 5 weeks
after surgery.
Randomization and treatment
Before randomization, each patient was physically examined, had
routine haematological testing and blood chemistry including
carcinoembryonic antigen (CEA), a chest radiogram and abdom-
inal sonography and/or computerized tomography (CT) scan.
Informed consent according to institutional regulations was
obtained from all patients. Eligible patients were registered by
phone at the central statistical office of the University of Vienna.
They were stratified according to participating centre, tumour
stage (II vs III with < 4 or .4 lymph nodes inwolved), extent of
invasion (into or through the serosa vs into adjacent organs) and
interval since surgery (< 21 vs 21-35 days).
They were then randomly assigned to adjuvant therapy with
FU/levamisole or i.v./i.p. FUALV according to the Zelen method
(Zelen, 1979). Dosages for FU and levamisole were the same as
those used in the National Intergroup Study (Moertel et al, 1990),
although patients were treated only for a total of 6 months.
Levamisole 50 mg was given orally every 8 h for a period of
3 days, repeated every 2 weeks. FU 450 mg m-2 was given by
rapid i.v. injection daily for 5 consecutive days; 28 days after the
start of the first course, FU was continued weekly. In the experi-
mental treatment arm, patients received LV 200 mg mi-2 and FU
350 mg m-2 both administered by i.v. bolus injection daily for
4 consecutive days. On days 1 and 3 of each treatment cycle, LV
and FU, each diluted in 500 ml ofsaline, were also given intraperi-
toneally in the same sequence and the samedosage. Intraperitoneal
drug administration was usually performed with a peripheral
venous catheter under local anaesthesia, although 14 patients
underwent surgical placement of an i.p. catheter attached to a
subcutaneous reservoir permitting transdermal access to the
catheter. Each 4-day course of i.p./i.v. adjuvant therapy was
repeated every 4 weeks for a total of six cycles. This particular
i.p./i.v. treatment schedule was based on a small pilot study and
our previous phase III trial (Scheithauer et al, 1995), indicating
potential therapeutic benefit and minimal toxicity despite use of a
cumulative dose of the drugs comparable with that of most
conventional i.v. FI/LV regimens used in the adjuvant/palliative
treatment setting.
Toxicity was assessed according to WHO standard criteria
(Miller et al, 1981). If stomatitis, diarrhoea, or leucopenia devel-
oped, chemotherapy was deferred until the side-effects subsided.
Iftoxicity persisted for more than 2 weeks, or ifitexceeded WHO
grade 2, the dose of FU was reduced by 20% in both treatment
arms. Complete blood cell counts were obtained every 2 weeks
during therapy, and serum electrolytes, liver and kidney function
parameters were repeated every 4 weeks.
Follow-up
All randomized patients were followed up for recurrence and
survival every 3 months during the first 2 years, thereafter every
6 months for a total of 5 years. Examinations consisted of an
interim history taking, physical examination and blood chemistry,
including CEA. Chest radiography, abdominal sonography and/or
CT scans and examination ofthe entire colorectum (barium enema
or endoscopy) was performed every 6 months and annually after
the second year. A documented histological diagnosis by percuta-
neous or colonoscopic biopsy or reoperation was required to
confirm recurrence of tumour, except in cases of lung or
liver metastases with unequivocal radiographic or scan changes.
British Journal ofCancer (1998) 77(8), 1349-1354 0CancerResearch Campaign 1998Adjuvant intraperitoneal + intravenous FU/LVin colon cancer 1351
Table 1 Patient characteristics
FU + levamisole
(n = 119)
Age (in years)
Median
Range
Sex
Male
Female
Location of primary tumour
Proximal to left flexura
More distant
Depth of invasion
pTl
pT2
pT3
pT4
Stage/nodal involvement
pT4 pNO MO
pTl-4 pNl MO
pTl-4 pN2,3 MO
Histological differentiation
Well
Moderate
Poor
Initiation of therapy
<21 days after surgery
21-35 days
63
33-75
64 (54%)
55 (46%)
57 (48%)
62 (52%)
1 (1%)
8 (7%)
67 (56%)
43 (36%)
20 (17%)
65 (55%)
34 (28%)
11 (9%)
86 (72%)
22 (19%)
77 (65%)
42 (35%)
i.p.ri.v. FU + leucovorin
(n = 117)
63
29-75
61 (52%)
56 (48%)
59 (50%)
58 (50%)
1 (1%)
9 (8%)
62 (53%)
45 (38%)
20 (18%)
64 (55%)
33 (28%)
8 (7%)
90 (77%)
19 (16%)
78 (67%)
39 (33%)
Abnormal CEA values were not used as evidence of relapse.
Disease-free survival was defined as the time from surgery to
relapse, the appearance of a second primary cancer or death,
whichever occurred first.
Statistical analysis
The primary efficacy end points ofthis study were overall survival
and disease-free survival. The target sample size for the study was
a minimum of 240 patients to ensure that the test would have a
power of 80% to detect a benefit in 5-year survival (ranging from
70% in the FU/levamisole group to 85% in the i.p./i.v. FU/LV
group) and an analogous benefit for disease-free time.
The proportion of patients disease-free or surviving was calcu-
lated using the Kaplan-Meier method (Kaplan and Meier, 1958).
The statistical difference between life-table distributions by treat-
ment was determined by the log-rank test (Mantel and Haenszel,
1959). Differences in the characteristics ofpatients were analysed
using the chi-squared test, and forward stepwise Cox regression
(Cox, 1972) was used in the evaluation of possible prognostic
factors influencing survival. All tests were two-sided.
RESULTS
Between June 1991 and January 1995, a total of 241 patients were
entered in this trial. Five patients were ineligible (two assigned to
adjuvant FU/levamisole and three to the experimental arm with
i.p./i.v. FUALV) for incorrect stage (n = 4) or histology (n = 1).
Ineligibility was not biased by treatment arm, and so these patients
were excluded from analysis. Thus, the study population consisted
of 236 randomized patients, 119 eligible in the FU/levamisole
arm and 117 in the combined locoregional plus i.v. systemic
chemotherapy arm. The characteristics ofthe study population are
shown in Table 1 and seem well balanced between the two treat-
ment arms. The two groups, in fact, were remarkably similar for
age, sex, location of primary tumour, histological grading and
pathological stage. Only 20 patients in both arms had stage II
(pT4NO) disease, all others had metastases to regional lymph
nodes. There was also no imbalance in terms of preoperative
complications such as intestinal obstruction or perforation, which
occurred in six patients and two patients in the FUl/evamisole
group and in five patients and three patients in the i.p./i.v. FU/LV
group respectively. The median follow-up time for this study is
now 4 years (range 2.5-6 years). Atpresent, 72 of236patients had
tumour recurrences. Ofthese, 46 are in the FU/levamisole arm and
26 in the investigational arm. At 48 months, 57.5% ofthe patients
receiving FU/levamisole and 77.3% of those receiving i.p./i.v.
chemotherapy are free of recurrence according to Kaplan-Meier
estimates (P = 0.0015). Plots of recurrence-free intervals for all
eligible patients are displayed in Figure 1, up to 60 months, at
which point fewer than 20% could be followed up. Our data
suggest that adjuvant i.p./i.v. chemotherapy provides not only
fewer recurrences but also a delay in observed recurrences. When
patients were divided into subsets according to stage, the advan-
tage for adjuvant i.p./i.v. FUILV was significant only in stage III
(P = 0.0014). Among all 40 patients with stage II disease, only
3 out of20 in the control arm and 2 outof20 in theFUI/LV arm had
tumour recurrences (P = 0.572). As it concerns the specific sites
of initial recurrence, a striking difference was found within
the abdominal cavity. Locoregional tumour recurrences with or
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Figure 1 Disease-free survival in patients with high-risk stage 11 (Dukes'
B2) and Ill colonic cancer randomized to adjuvant combined intraperitoneal
(i.p.) and intravenous (i.v.) FU/leucovorin or to FU/levamisole. In the i.p.A.v.
FU/LV group (-), of 117 at-risk patients, 26 relapsed. In the FU/levamisole
group (-), of 119 at-risk patients, 46 relapsed
without liver or other organ site involvement occurred in 25
patients in the FU/levamisole arm (13 locoregional only, eight
locoregional + liver, and four locoregional + other distant sites)
compared with ninepatients in the FU/LV arm (P = 0.005; Table 2).
A less striking difference was seen if patients were analysed for
intrahepatic tumour recurrences. Twenty-three patients had liver
recurrences with or without other organ sites at the flrst site of
treatment failure in the FU/levamisole arm, as did 14 patients with
documented recurrences in the experimental arm (P = 0.15). There
were no differences in terms of frequency or sites of recurrences
outside the abdomen.
Survival according to study arm is shown in Figure 2. At the
time ofwriting, 59 patients with recurrent disease have died: 41 on
the FU/levamisole arm, and 18 who received adjuvant i.p./i.v.
FU/LV. The estimated reduction in mortality rate using combined
adjuvant i.p./i.v. FUJ/LV compared with FU/levamisole was
43% (95% confidence interval, 26-70%). Thirteen patients died
without evidence of recurrence: eight on the FU/levamisole
arm and five who received i.p./i.v. FU/LV; deaths were largely
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Figure 2 Overall survival of high-risk stage 11 (Dukes' B2) and Ill colonic
cancer randomized to adjuvant combined intraperitoneal (i.p.) and
intravenous (i.v.) FUAleucovorin or to FU/levamisole. In the i.pAi.v. FU/LV
group (-), of 117 at-risk patients, 18 died. In the FU/levamisole group
(-), of 119 at-risk patients, 41 died
cardiovascular. There are 13 patients with documented recurrence
who are still alive: five in the control arm and eight in the experi-
mental arm (four of these patients in the FU/levamisole arm and
five in the FU/LV arm had undergone potential curative surgery
for recurrent disease). This makes it probable that the survival
advantage ofi.p./i.v. FU/LV will be sustained. The 4-year survival
estimates are 65% for the control arm and 83% for the experi-
mental arm (P = 0.0004). Analysis of patients according to stage
again suggested a distinct advantage for combined i.p./i.v.
chemotherapy only in those with stage III disease (P = 0.0005).
The factors of prognostic significance for survival (P = 0.05)
included the number of metastatic lymph nodes and the depth of
invasion. After adjustment for imbalances among prognostic vari-
ables, adjuvant therapy with i.p./i.v. FU/LV was confirmed to have
a significant advantage over FU/levamisole (P = 0.0008).
The frequency and grades of treatment-associated side-effects
are presented according to treatment arm in Table 3. Overall,
adverse reactions were relatively uncommon and they were gener-
ally mild to moderate. None ofthe patients in either treatment arm
Table 2 Sites of first treatment failure
FU + levamisole %
(n = 119)
i.pii.v. FU + leucovorin %
(n = 117)
Recurrence
Intra-abdominal
Liver
Liver + locoregional
Locoregional
Carcinosis + omentum
Abdominal/retroperitoneal LNNa
Anastomotic
Extra-abdominal
Lung
CNS
Bone
Intra- + extra-abdominal
Liver + lung
Locoregional + lung
Locoregional + ovary/abdominal wall
Second primary
26 (22%) 46 (39%)
12 (10%)
8 (7%)
13 (11%)
6 (5%)
4 (3%)
3 (3%)
4 (3%)
1 (1%)
3 (3%)
2 (2%)
2 (2%)
1 (1%)
9 (8%)
2 (2%)
5 (4%)
2 (2%)
2 (2%)
1 (1%)
1 (1%)
1 (1%)
1 (1%)
3 (3%)
2 (2%)
2 (2%)
aLymph nodes.
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Table 3 Treatment-associated side-effects
Toxicity World Health FU + i.pJIi.v. FU +
Organization levamisole leucovorin
grade* (n = 119) (n = 117)
Nausea/vomiting
Diarrhoea
Stomatitis
Leucopenia
Granulocytopenia
Thrombocytopenia
Anaemia
Infection
Alopecia
Dermatitis
Conjunctivitis
Peripheral neurotoxicity
CNS toxicity
Impaired liver function
Abdominal pain
2
3
2
3
2
3
2
3
4
2
3
4
1
2
2
3
2
3
2
17
11
1
12
61
6 9
5
19
8
4
1
18 10
5
2
5
0
10
5
10
4
1
4
2
1
9
2
3
6
2
2
2
5
2
0
2
2
2
13
8
0
7
4
1
9
4
1
18
4
0
0
15
11
1
0
2
1
3
0
4
1
0
5
0
0
6
1
5
2
0
0
0
0
15
7
experienced any life-threatening side-effects, and there were no
treatment-related deaths. Gastrointestinal symptoms consisted of
nausea/vomiting in 24% and 18%, diarrhoea in 16% and 10%, and
mucositis in 17% and 12% in the FU/levamisole and i.p./i.v.
FU/LV arm respectively. Haematological toxicity included granu-
locytopenia in 29% vs 23%, thrombocytopenia in 5% vs 3% and
anaemia in 13% vs 3%. Mild and reversible hepatic toxicity and
neurological symptoms including CNS toxicity were occasionally
seen in patients treated with FU/levamisole. Abdominal pain
during orshortly afteri.p. drug administration was noted in 19% in
the experimental treatment arm. Overall, slightly more than one-
third of the patients in both treatment groups had no symptoms
during therapy, and slightly more than half (53% in the
FU/Aevamisole arm and 56% in the i.p./i.v. FU/LV arm) had
experienced mild to moderate symptoms (WHO grade 1-2).
Severe adverse reactions (2 WHO grade 3) requiring a 20% dose
reduction of FU, however, were more common in the
FUflevamisole arm than in the experimental arm (13% vs 3%,
P = 0.01). Interval adjustments were necessary in 33 vs 13 patients.
This was due to toxicity in 15 vs 3, compliance in 12 vs 3, and for
other reasons such as for personal reasons or for reoperation of
colostomy in six and seven patients. Treatment was discontinued
early, i.e. before 6 months in 25% vs 13% of patients. Premature
discontinuation was due to compliance in 10% in both anns
because of recurrence or death in 7% vs 3%, and due to toxicity
only in the levamisole arm (8%).
DISCUSSION
Adjuvant intraperitoneal chemotherapy has not yet undergone
sufficient clinical evaluation in patients withresected colon cancer.
Despite the appealing rationale of counteracting microscopic
residual disease by delivering high concentrations ofdrug to local
intraperitoneal surfaces and, if there is sufficient hepatic extrac-
tion, also to the liver, clinical experience in gastrointestinal cancer
is limited, with only its feasibility and tolerance so far demon-
strated (Nordlinger et al, 1990; Rougier and Nordlinger, 1993).
Based on the results ofarecently published prospective evaluation
of this locoregional therapeutic concept combined with systemic
intravenous FU/leucovorin chemotherapy in patients with high-
risk stage II and III colon cancer, which suggested substantial
therapeutic gain compared with surgery alone (Scheithauer et al,
1995), the present study was initiated; the former control arm
of the study was replaced by 'standard chemotherapy' with
FU/levamisole given for a duration of 6 months. In the primary
analysis of this study, including all patients randomized, the
experimental arm with combined i.p./i.v. FU/leucovorin showed a
significant advantage in the recurrence rate after a median follow-
up time of 48 months, with a longer disease-free and overall
survival. The therapeutic advantage was restricted to patients with
stage III disease; in those with high-risk stage II (T4NOMO)
disease, the sample size was much too small to elucidate such an
effect and thus allow any conclusions. In agreement with its theo-
retical concept and the results of our previous phase III trial, the
experimental arm was particularly effective in reducing loco-
regional (9 vs 25 patients) tumour recurrences, and, although to a
lesser degree, also intrahepatic (14 vs 23 patients) recurrences. The
lower incidence of liver metastases than generally observed in
controlled adjuvant trials ofportal vein drug administration (Laffer
and Metzger, 1995) could be explained by use of a more effective
drug regimen using biochemical modulation of FU, the additive
effects of systemic intravenous and intraperitoneal drug adminis-
tration, and the much longer duration of treatment, i.e. 180 rather
than 5-7 days, as generally used in trials of adjuvant portal vein
cytotoxic perfusion.
An important advantage of the i.p./i.v. FU/LV regimen used in
this study represents the minimal treatment-associated toxicity and
the resultant excellent patient compliance with 87% completing
the prescribed number of six treatment cycles. Despite a cumula-
tive dose of 2100 mg m-2 FU per treatment cycle, which is similar
to that of most conventional i.v. FUJ/LV regimens (1850-
2000 mg m-2 in case of monthly, and 2400 mg m-2 in case of
weekly administration schedules) (Advanced Colorectal Cancer
Meta-Analysis Project, 1992), severe (WHO grade 3) adverse
reactions were noted in only 3% compared with 13% in
the FU/levamisole arm. The minimal toxicity observed in the
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experimental arm is likely to be related to an improved therapeutic
index ifchemotherapy (or at least one-third of the drug dosage) is
given intraperitoneally (Speyer, 1985).
One possible drawback of this study, apart from the still limited
duration of follow-up, may be that adjuvant therapy with
FU/levamisole was given only for 6 months in the control arm,
rather than for 12 months as in the original protocol. A recently
published prospective evaluation of chemotherapy duration and
regimen by the North Central Cancer Treatment Group and the NCI
of Canada suggested that 6 months of FU/levamisole was inferior
to 12 months (O'Connell et al, 1996). The considerable proportion
of patients prematurely discontinuing treatment (after a median of
5 months) because of toxicity and practical problems involved in
the use ofFU/levamisole, as noted in the Intergroup study (Moertel
et al, 1990) and by other investigators using a 12-month schedule
(Wassner and Heidemann, 1996), however, seem to attenuate the
importance/influence of this potentially confounding factor. In
addition, the death rate in the FU/levamisole arm of the present
study (10% for stage II and 29% for stage III) seems almost the
same as that of the Intergroup study reported after 3.5 years (12%
for stage II and 26% for stage III; Moertel et al, 1990), despite the
difference in treatment duration.
Although the relative importance of intraperitoneal instillation
ofchemotherapeutic drugs remains to be determined, early results
of this trial let us conclude that this site-of-recurrence-oriented
adjuvant treatment approach may represent one of several other
promising leads to be followed to further improve survival in this
common malignant disease. The results ofother clinical trials that
have also been initiated in order to define the role of regional and
systemic chemotherapy (in the early post-operative adjuvant
setting) (Koehne-Wompner et al, 1994) are awaited with interest.
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